Der Nephrologe

, Volume 6, Issue 1, pp 68–69 | Cite as

Alemtuzumab (Campath-1H)

Nephro molekular

Alemtuzumab (Campath-1H)

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Calne R, Moffatt SD, Friend PJ et al (1999) Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68(10):1613–1616CrossRefPubMedGoogle Scholar
  2. 2.
    Calne R, Friend P, Moffatt S et al (1998) Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351(9117):1701–1702CrossRefPubMedGoogle Scholar
  3. 3.
    Kirk AD, Hale DA, Mannon RB et al (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76(1):120–129CrossRefPubMedGoogle Scholar
  4. 4.
    Knechtle SJ, Pirsch JD, Fechner H et al (2003) Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 3(6):722–730CrossRefPubMedGoogle Scholar
  5. 5.
    Rao V, Pirsch JD, Becker BN, Knechtle SJ (2003) Sirolimus monotherapy following Campath-1H induction. Transplant Proc 35(3 Suppl):128S–130SCrossRefPubMedGoogle Scholar
  6. 6.
    Flechner SM, Friend PJ, Brockmann J et al (2005) Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 5(12):3009–3014CrossRefPubMedGoogle Scholar
  7. 7.
    Ciancio G, Burke GW, Gaynor JJ et al (2004) The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 78(3):426–433CrossRefPubMedGoogle Scholar
  8. 8.
    Knechtle SJ, Fernandez LA, Pirsch JD et al (2004) Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 136(4):754–760CrossRefPubMedGoogle Scholar
  9. 9.
    Baez Y, Giron F, Niño-Murcia A et al (2008) Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression. Transplant Proc 40(3):697–699CrossRefPubMedGoogle Scholar
  10. 10.
    Ortiz J, Palma-Vargas J, Wright F et al (2008) Campath induction for kidney transplantation: report of 297 cases. Transplantation 85(11):1550–1556CrossRefPubMedGoogle Scholar
  11. 11.
    Kaufman DB, Leventhal JR, Axelrod D et al (2005) Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction – long-term results. Am J Transplant 5(10):2539–2548CrossRefPubMedGoogle Scholar
  12. 12.
    Tan HP, Kaczorowski DJ, Basu A et al (2006) Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 6(10):2409–2417CrossRefPubMedGoogle Scholar
  13. 13.
    Clatworthy MR, Friend PJ, Calne RY et al (2009) Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 87(7):1092–1095CrossRefPubMedGoogle Scholar
  14. 14.
    Tan HP, Donaldson J, Basu A et al (2009) Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 9(2):355–366CrossRefPubMedGoogle Scholar
  15. 15.
    Huang E, Cho YW, Hayashi R, Bunnapradist S (2007) Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 84(7):821–828CrossRefPubMedGoogle Scholar
  16. 16.
    Sampaio MS, Kadiyala A, Gill J, Bunnapradist S (2009) Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation. Transplantation 88(7):904–910CrossRefPubMedGoogle Scholar
  17. 17.
    Vathsala A, Ona ET, Tan SY et al (2005) Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80(6):765–774CrossRefPubMedGoogle Scholar
  18. 18.
    Thomas PG, Woodside KJ, Lappin JA et al (2007) Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 83(11):1509–1512CrossRefPubMedGoogle Scholar
  19. 19.
    Ciancio G, Burke GW, Gaynor JJ et al (2008) A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 22(2):200–210CrossRefPubMedGoogle Scholar
  20. 20.
    Margreiter R, Klempnauer J, Neuhaus P et al (2008) Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant 8(7):1480–1485CrossRefPubMedGoogle Scholar
  21. 21.
    Farney AC, Doares W, Rogers J et al (2009) A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 88(6):810–819CrossRefPubMedGoogle Scholar
  22. 22.
    Basu A, Ramkumar M, Tan HP et al (2005) Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 37(2):923–926CrossRefPubMedGoogle Scholar
  23. 23.
    Bartosh SM, Knechtle SJ, Sollinger HW (2005) Campath-1H use in pediatric renal transplantation. Am J Transplant 5(6):1569–1573CrossRefPubMedGoogle Scholar
  24. 24.
    Shapiro R, Ellis D, Tan HP et al (2007) Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J Transplant 7(12):2736–2738CrossRefPubMedGoogle Scholar
  25. 25.
    Nishida S, Levi D, Kato T et al (2002) Induction therapy for adult small bowel transplant with Campath-1H. Transplant Proc 34(5):1889–1891CrossRefPubMedGoogle Scholar
  26. 26.
    Reams BD, Davis RD, Curl J, Palmer SM (2002) Treatment of refractory acute rejection in a lung transplant recipient with campath 1H. Transplantation 74(6):903–904CrossRefPubMedGoogle Scholar
  27. 27.
    Tzakis AG, Kato T, Nishida S et al (2002) Campath-1H in intestinal and multivisceral transplantation: preliminary data. Transplant Proc 34(3):937CrossRefPubMedGoogle Scholar
  28. 28.
    Tzakis AG, Kato T, Nishida S et al (2003) Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation 75(8):1227–1231CrossRefPubMedGoogle Scholar
  29. 29.
    Burt RK, Verda L, Statkute L et al (2004) Stem cell transplantation for autoimmune diseases. Clin Adv Hematol Oncol 2(5):313–319PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Abteilung für Nephrologie und TransplantationsmedizinMedizinische Klinik III, Westpfalz-KlinikumKaiserslauternDeutschland

Personalised recommendations